A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

NCT03547167 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1515

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infections

Interventions

BIOLOGICAL: V114
BIOLOGICAL: Prevnar 13™
BIOLOGICAL: PNEUMOVAX™23

Sponsor

Merck Sharp & Dohme LLC